Clinical Trials for Skin Cancer
571 skin cancer trials indexed, 264 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Skin Cancer
Skin cancer is a disease where abnormal skin cells grow uncontrollably. It usually starts in the outer layer of the skin, called the epidermis. The most common types are basal cell carcinoma, squamous cell carcinoma, and melanoma. These cancers develop when DNA damage in skin cells causes them to divide and grow without control. Diagnosis often involves a physical exam and a biopsy, where a small skin sample is taken and examined under a microscope. Doctors look for changes in cell shape, size, and organization to confirm the presence of cancer.
Common symptoms of skin cancer include new or changing moles, sores that do not heal, and unusual skin growths. The typical age of onset varies by type but is often in adults over 50 years old. However, melanoma can occur in younger individuals as well. People with fair skin, a history of sunburns, excessive sun exposure, or a family history of skin cancer are at higher risk. Other risk factors include weakened immune systems and exposure to certain chemicals. Regular skin checks are important for early detection, especially for those at increased risk.
Skin cancer is a significant medical and social concern. It is the most common cancer in the United States, with over 5 million cases diagnosed each year. Melanoma alone causes about 7,000 deaths annually in the U.S. Early detection and treatment are critical because some skin cancers can spread to other parts of the body. The economic burden is also high, with treatment costs reaching billions of dollars annually. These factors make skin cancer a focus of ongoing medical research and public health efforts.
The Skin Cancer Treatment Landscape
The first-line treatment for most skin cancers is surgery to remove the tumor. This approach aims to excise the cancer completely while preserving as much healthy tissue as possible. For basal and squamous cell carcinomas, surgery is often curative. In some cases, radiation therapy is used as the initial treatment or after surgery to reduce the risk of recurrence. Early-stage melanoma is usually treated with surgery alone, while more advanced cases require additional therapies. Treatment decisions depend on the cancer type, size, location, and whether it has spread.
For patients who do not respond to surgery or radiation, second- and third-line treatments include targeted therapies and immunotherapies. Targeted drugs block specific molecules involved in cancer growth, such as BRAF inhibitors for melanoma patients with BRAF gene mutations. Immunotherapy drugs, such as checkpoint inhibitors, help the immune system recognize and attack cancer cells. Chemotherapy is less common but may be used in advanced cases. These options provide additional hope for patients with more aggressive or treatment-resistant skin cancers.
Despite advances, gaps remain in skin cancer treatment. Some patients develop resistance to targeted drugs or immunotherapies, leading to disease progression. Side effects from treatments can also be severe, affecting quality of life. Certain subgroups, such as those with rare types of skin cancer or with tumors in difficult locations, may have fewer effective options. Research is focused on understanding resistance mechanisms, improving drug tolerability, and finding new therapies. Clinical trials play a key role in exploring these areas.
Why Clinical Trials Matter for Skin Cancer
Clinical trials offer patients access to new treatments that are not yet widely available. Participating in a trial often means closer medical monitoring and support from a research team. This can be especially valuable for patients with advanced or difficult-to-treat skin cancers. According to ClinicalTrials.gov, there are currently 571 skin cancer clinical trials indexed, with 264 actively recruiting participants. These trials cover a range of approaches, including novel drugs, combination therapies, and new diagnostic tools. Patients contribute to medical knowledge that may benefit future patients.
While clinical trials provide potential benefits, they also carry risks. Some treatments may not work as hoped, and new drugs can have unknown side effects. Trials often include placebo groups or standard treatment comparisons, which means not all participants receive the experimental therapy. Additional clinic visits and tests may be required, which can be time-consuming. Patients should carefully discuss the trial details with their healthcare team to understand the possible risks and benefits before enrolling.
The sponsors of skin cancer clinical trials include academic institutions, pharmaceutical companies, and cooperative research groups. Each sponsor type plays a role in advancing treatment options. ClinicalTrials.gov serves as a public registry that tracks these studies, providing transparency and helping patients and doctors find relevant trials. This registry is an important resource for anyone interested in learning about ongoing research and available opportunities to participate.
What to Look for in a Skin Cancer Clinical Trial
Clinical trials for skin cancer are divided into phases 1 through 4, each with a different goal. Phase 1 trials test the safety of a new treatment in a small group of people. Phase 2 trials focus on how well the treatment works and continue to evaluate safety. Phase 3 trials compare the new treatment to the current standard to see which is better. Phase 4 trials happen after a treatment is approved to monitor long-term effects. For skin cancer, most trials are in Phase 2, with 211 studies. There are 165 Phase 1 trials, 56 Phase 3 trials, and 51 trials with no phase specified.
When looking at inclusion criteria for skin cancer trials, several factors are common. Age ranges often vary but typically include adults 18 years and older. Some trials require patients to have specific types or stages of skin cancer, such as melanoma or non-melanoma, and may specify disease duration. Prior treatments are also important; many trials require participants to have had certain therapies before joining. Biomarkers, like genetic mutations or protein expression, may be needed to qualify for targeted treatments. Staging of cancer helps determine eligibility, with some trials focusing on early-stage disease and others on advanced cases.
Exclusion criteria are just as important to understand. These rules help protect patients and ensure clear results. People with serious other health conditions, known as comorbidities, may be excluded because these could interfere with the treatment or cause complications. Drug interactions are another concern; patients taking certain medications might not be eligible. Safety thresholds, such as minimum blood counts or organ function levels, are set to reduce risks during the trial. These criteria help keep participants safe and the study data reliable.
Patients should also think about practical aspects before joining a skin cancer trial. Trial duration can range from a few months to several years, depending on the study. The visit schedule may require frequent trips to the clinic for tests or treatment. Travel distance and costs can be a challenge for some people. It is helpful to ask the research team specific questions, such as: How often will I need to come in? What side effects should I expect? Are there costs I will need to cover? What happens if I decide to leave the trial early? These questions can help patients prepare and feel more comfortable with their decision.
Primary Sources and Further Reading
For those interested in learning more about skin cancer and clinical trials, it is important to consult reliable sources. These websites offer detailed information on skin cancer types, treatment options, and ongoing research. They also provide guidance on how to find and participate in clinical trials. Below are some trusted resources to explore further.
- National Cancer Institute: Skin Cancer
- MedlinePlus: Skin Cancer
- ClinicalTrials.gov: Skin Cancer Trials
- Centers for Disease Control and Prevention: Skin Cancer
Latest Research and Emerging Treatments for Skin Cancer (2026)
Skin cancer research is exploring new drugs and treatment combinations to improve patient outcomes. One study is testing NBTXR3, a nanoparticle activated by radiotherapy, with or without cetuximab for advanced head and neck cancers (NCT04892173). NBTXR3 works by enhancing the effect of radiation directly within the tumor, which may help control cancer growth more effectively. Cetuximab is a monoclonal antibody that blocks signals cancer cells use to grow. This combination could offer a skin cancer treatment option for elderly patients who cannot tolerate traditional chemotherapy.
Another area of research involves immunotherapy drugs like pembrolizumab, which helps the immune system recognize and attack cancer cells. Trials are testing pembrolizumab alone or combined with lenvatinib, a drug that may block blood vessel growth in tumors (NCT05523323, NCT04199104). Early data suggests adding lenvatinib could improve response rates and delay disease progression in patients with PD-L1 positive tumors. For patients, these new drugs for skin cancer might mean more effective first-line treatments with potentially fewer side effects than chemotherapy.
Radiation therapy techniques are also evolving in skin cancer treatment. Studies are comparing proton therapy to traditional photon radiation to see if proton therapy can treat tumors while reducing damage to healthy tissue (NCT03801876). Another trial is evaluating whether giving radiation in smaller, multiple doses improves brain metastasis control compared to a single large dose (NCT06500455). These approaches aim to improve quality of life by lowering side effects during treatment. Together, these trials represent ongoing efforts in skin cancer research to expand treatment choices and improve patient experiences in 2026.
Frequently asked questions about Skin Cancer trials
How do I find Skin Cancer clinical trials?
The authoritative source for Skin Cancer clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 571 skin cancer studies are currently indexed. You can search by entering "skin cancer" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new skin cancer trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Skin Cancer trials in?
Across the 571 skin cancer trials TrialsAlert indexes, the most common phase is Phase 2. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Skin Cancer clinical trials are currently recruiting?
As of the latest scan, 264 skin cancer trials have a "Recruiting" status on ClinicalTrials.gov, out of 571 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting skin cancer trial matches their tracked condition.
Stay informed about skin cancer research
Get a weekly briefing with the trials that matter most.